These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7652488)

  • 41. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
    J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance characteristics and quality control of community based ultrasound surveys for cystic and alveolar echinococcosis.
    Macpherson CN; Milner R
    Acta Trop; 2003 Feb; 85(2):203-9. PubMed ID: 12606098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarkers--the key to the clinical development of chemopreventives.
    Sikora K
    Eur J Cancer Prev; 2004 Aug; 13(4):237-8. PubMed ID: 15554549
    [No Abstract]   [Full Text] [Related]  

  • 45. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Liquid biopsies, a revolution in oncology?].
    Jordan B
    Med Sci (Paris); 2015; 31(8-9):805-7. PubMed ID: 26340842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
    Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor markers for breast cancer. Current utilities and future prospects.
    Hayes DF
    Hematol Oncol Clin North Am; 1994 Jun; 8(3):485-506. PubMed ID: 8707769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
    Lam L; Woollard GA; Teague L; Davidson JS
    Ann Clin Biochem; 2017 Mar; 54(2):264-272. PubMed ID: 27235704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour markers in oncology: past, present and future.
    Magdelénat H
    J Immunol Methods; 1992 Jun; 150(1-2):133-43. PubMed ID: 1613250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
    Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
    Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions.
    Huddy JR; Ni MZ; Markar SR; Hanna GB
    World J Gastroenterol; 2015 Apr; 21(14):4111-20. PubMed ID: 25892860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular markers for colorectal cancer screening.
    Dickinson BT; Kisiel J; Ahlquist DA; Grady WM
    Gut; 2015 Sep; 64(9):1485-94. PubMed ID: 25994221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
    Tomlinson IP; Whyman A; Barrett JA; Kremer JK
    Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current trends and emerging diagnostic techniques for lung cancer.
    Prabhakar B; Shende P; Augustine S
    Biomed Pharmacother; 2018 Oct; 106():1586-1599. PubMed ID: 30119234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
    Byström P; Berglund A; Nygren P; Wernroth L; Johansson B; Larsson A; Einarsson R; Glimelius B
    Oncol Rep; 2010 Dec; 24(6):1645-52. PubMed ID: 21042763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
    Pecking AP; Mechelany-Corone C; Pichon MF
    Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.